WO2024259323A3 - Pharmaceutical compositions for targeted delivery of bioactive agents with improved bioavailability and methods of use - Google Patents

Pharmaceutical compositions for targeted delivery of bioactive agents with improved bioavailability and methods of use Download PDF

Info

Publication number
WO2024259323A3
WO2024259323A3 PCT/US2024/034128 US2024034128W WO2024259323A3 WO 2024259323 A3 WO2024259323 A3 WO 2024259323A3 US 2024034128 W US2024034128 W US 2024034128W WO 2024259323 A3 WO2024259323 A3 WO 2024259323A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
targeted delivery
bioactive agents
methods
improved bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/034128
Other languages
French (fr)
Other versions
WO2024259323A2 (en
Inventor
Scott Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP24824277.8A priority Critical patent/EP4727581A2/en
Publication of WO2024259323A2 publication Critical patent/WO2024259323A2/en
Publication of WO2024259323A3 publication Critical patent/WO2024259323A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides therapeutic and pharmaceutical compositions for topical application and targeted delivery of bioactive agents with improved drug bioavailability to a subject, wherein the composition comprises i) an anhydrous carrier; ii) an effective amount of a bioactive agent; and iii) a penetration enhancer selected from the group consisting of an amino acid derivative compound, a cell penetrating peptide (CPP), an antimicrobial peptide, a lipid nanoparticle composition, and combinations thereof.
PCT/US2024/034128 2023-06-14 2024-06-14 Pharmaceutical compositions for targeted delivery of bioactive agents with improved bioavailability and methods of use Ceased WO2024259323A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24824277.8A EP4727581A2 (en) 2023-06-14 2024-06-14 Pharmaceutical compositions for targeted delivery of bioactive agents with improved bioavailability and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508175P 2023-06-14 2023-06-14
US63/508,175 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024259323A2 WO2024259323A2 (en) 2024-12-19
WO2024259323A3 true WO2024259323A3 (en) 2025-01-23

Family

ID=93852837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034128 Ceased WO2024259323A2 (en) 2023-06-14 2024-06-14 Pharmaceutical compositions for targeted delivery of bioactive agents with improved bioavailability and methods of use

Country Status (2)

Country Link
EP (1) EP4727581A2 (en)
WO (1) WO2024259323A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171490A1 (en) * 2005-02-07 2014-06-19 Pharmalingt Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20160199498A1 (en) * 2013-08-12 2016-07-14 3M Innovative Properties Company Peptides for enhancing transdermal delivery
US20200009040A1 (en) * 2017-02-07 2020-01-09 Myocept Inc. Topical formulations and methods
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171490A1 (en) * 2005-02-07 2014-06-19 Pharmalingt Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20160199498A1 (en) * 2013-08-12 2016-07-14 3M Innovative Properties Company Peptides for enhancing transdermal delivery
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system
US20200009040A1 (en) * 2017-02-07 2020-01-09 Myocept Inc. Topical formulations and methods

Also Published As

Publication number Publication date
WO2024259323A2 (en) 2024-12-19
EP4727581A2 (en) 2026-04-22

Similar Documents

Publication Publication Date Title
EP2025337B1 (en) Pharmaceutical composition for external use
Hartmann et al. Toxicity of platinum compounds
US10888622B2 (en) Nanocomplexes of modified peptides or proteins
AU2011227083B2 (en) Stable bortezomib formulations
US8263578B2 (en) Stable bortezomib formulations
EP1478372B1 (en) Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
US20110245501A1 (en) Substituted Tetracycline Compounds as Synergistic Antifungal Agents
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
CA2492976A1 (en) Solution for ungual and peri-ungual application
WO2004104018A3 (en) Compositions for delivering peptide yy and pyy agonists
DK2143429T3 (en) Use of cilastatin for reducing the nephrotoxicity of various compounds
WO2005028516A3 (en) Albumin-binding derivatives of therapeutic peptides
KR20150034685A (en) Topical non-aqueous pharmaceutical formulations
US11590233B2 (en) Porphyrin compounds and compositions useful for treating cancer
Nudelman Mutual prodrugs-codrugs
EP2644189A1 (en) Stable bortezomib formulations
US20230105108A1 (en) Compounds for the treatment of bacterial infections and potentiation of antibiotics
WO2024259323A3 (en) Pharmaceutical compositions for targeted delivery of bioactive agents with improved bioavailability and methods of use
US10125167B2 (en) Compositions and methods for treating MRSA infections and for sensitizing MRSA to beta-lactam antibiotics
AU2004257450B2 (en) Parasiticidal composition
WO2003072112A1 (en) 'long'-'acting' injectable parasiticidal composition
US20040166148A1 (en) Transdermal therapeutic delivery systems with a butenolide
US10835615B2 (en) Supramolecular hydrogels containing angiotensin receptor blockers for targeted treatment of diabetic wounds
US8697712B2 (en) Presentation of an antiviral pharmaceutical composition
CA3211371A1 (en) Stapled antimicrobial peptides (stamps) and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024824277

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824277

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

WWP Wipo information: published in national office

Ref document number: 2024824277

Country of ref document: EP